Bone Marrow Transplantation in Treating Patients With Leukemia
Phase 3
Withdrawn
- Conditions
- LeukemiaGraft Versus Host DiseaseLymphoma
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00006451
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
Phase 2
Terminated
- Conditions
- Leukemia
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00005986
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2
Withdrawn
- Conditions
- Lymphoma
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00005998
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Phase 1
Terminated
- Conditions
- ChordomaLiver CancerNeuroblastomaRetinoblastomaOvarian CancerSarcomaChildhood Germ Cell TumorKidney CancerBrain and Central Nervous System Tumors
- Interventions
- Procedure: peripheral blood stem cell transplantation (PBSC)
- First Posted Date
- 2003-05-02
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 13
- Registration Number
- NCT00003926
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Phase 2
Terminated
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 87
- Registration Number
- NCT00005987
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 213
- Registration Number
- NCT00005985
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
Phase 2
Terminated
- Conditions
- Leukemia
- Interventions
- Procedure: peripheral blood stem cell transplantationProcedure: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 22
- Registration Number
- NCT00005984
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Vaccination With Tetanus and KLH to Assess Immune Responses.
Terminated
- Conditions
- Cancer
- Interventions
- Biological: Biosyn KLHBiological: Intracel KLH VaccineBiological: Tetanus toxoid
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 112
- Registration Number
- NCT00000105
- Locations
- 🇺🇸
Division of Hematology, Oncology, and Transplantation 420 Delaware St., SE, Box 806 Mayo, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath